Assessing Biohaven (BHVN) Valuation After Prolonged Share Price Weakness And Elevated P/B Ratio

Simply Wall St.

May 03

AdvertisementRecent share performance and business profile Biohaven (BHVN) has drawn investor attention after a period of weaker share returns, including an 18% decline over the past 3 months and a ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2632600178"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2632600178\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2632600178?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-05-03 21:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2632600178","market":"us","top_or_hot":-1,"title":"Assessing Biohaven (BHVN) Valuation After Prolonged Share Price Weakness And Elevated P/B Ratio","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementRecent share performance and business profile Biohaven (BHVN) has drawn investor attention after a period of weaker share returns, including an 18% decline over the past 3 months and a ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/assessing-biohaven-bhvn-valuation-after-prolonged-share-pric\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Biohaven (BHVN) Valuation After Prolonged Share Price Weakness And Elevated P/B Ratio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Biohaven (BHVN) Valuation After Prolonged Share Price Weakness And Elevated P/B Ratio\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-03 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/assessing-biohaven-bhvn-valuation-after-prolonged-share-pric><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementRecent share performance and business profile Biohaven (BHVN) has drawn investor attention after a period of weaker share returns, including an 18% decline over the past 3 months and a ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/assessing-biohaven-bhvn-valuation-after-prolonged-share-pric\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1093756325.SGD","symbol_name":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/assessing-biohaven-bhvn-valuation-after-prolonged-share-pric","article_id":"2632600178","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/assessing-biohaven-bhvn-valuation-after-prolonged-share-pric","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2632600178","pubTimestamp":1777814873,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Recent share performance and business profile\nBiohaven (BHVN) has drawn investor attention after a period of weaker share returns, including an 18% decline over the past 3 months and a 57.86% drop over the past year.\nThe company focuses on developing treatments across immunology, neuroscience, and oncology, with multiple drug candidates in Phase 2 and Phase 3 clinical trials. It has a market capitalization of about US$1.45b.\nSee our latest analysis for Biohaven.\nAt a share price of US$9.63,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4139":"生物科技","BHVN":"Biohaven Pharmaceutical Holding Co Ltd."},"translate_title":"在股价长期疲软和市净率上升后评估Biohaven(BHVN)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BHVN":1.5},"content_text":"AdvertisementRecent share performance and business profile Biohaven (BHVN) has drawn investor attention after a period of weaker share returns, including an 18% decline over the past 3 months and a 57.86% drop over the past year. The company focuses on developing treatments across immunology, neuroscience, and oncology, with multiple drug candidates in Phase 2 and Phase 3 clinical trials. It has a market capitalization of about US$1.45b. See our latest analysis for Biohaven. At a share price of US$9.63, Biohaven’s short term share price return has been weak, and the 1 year total shareholder return of a 57.86% decline points to fading momentum despite progress across its pipeline. If this kind of volatility has you looking wider, now could be a good time to scan other healthcare names tapping into AI, starting with 33 healthcare AI stocks After such weak recent returns, Biohaven trades at about US$9.63 while the average analyst price target sits near US$22.24. Should you view this as a discount entry point, or assume the market is already pricing in future growth? Preferred Price-to-Book Multiple of 27.8x: Is it justified? On a P/B basis, Biohaven trades on a multiple of 27.8x, which is high next to peers and the wider US biotechs industry, despite a share price of $9.63 and recent weak returns. The P/B ratio compares a company’s market value to its book value. For an early stage, loss-making biotech like Biohaven, a high P/B often reflects how much investors are willing to pay today for a pipeline that is yet to translate into revenue or profits. Here, that willingness is stretched, as Biohaven currently reports no revenue, a net loss of $738.8m and a negative return on equity of 1,418.85%, while also having less than one year of cash runway and relying entirely on higher risk funding sources. Compared with both its peer group average P/B of 19.7x and the broader US biotechs industry average of 2.3x, Biohaven’s 27.8x ratio stands out as significantly richer. This means the market is assigning a much higher price tag to its assets than is typical in the sector. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-book of 27.8x (OVERVALUED) However, the story can change quickly if clinical trials disappoint or if fresh funding becomes harder to secure for this loss making, cash constrained business. Find out about the key risks to this Biohaven narrative. Next Steps If the recent tone feels cautious, that is exactly why it helps to move quickly and review the underlying data yourself, including the 4 important warning signs Looking for more investment ideas? Biohaven may have caught your eye, but your portfolio deserves fresh options that match your goals and risk comfort, so do not stop your research here.  Target potential mispricing by scanning companies that combine quality fundamentals with attractive valuations using the 50 high quality undervalued stocks. Strengthen your income stream by checking out stocks with generous yields and staying power through the 13 dividend fortresses. Protect your capital by focusing on companies with lower risk profiles and resilient characteristics through the 69 resilient stocks with low risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Biohaven might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}